NCT01678417

131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma

A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Follicular or Mantle Cell Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (estimated)
• Sponsor: Korea Cancer Center Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Follicular lymphoma (FL) and mantle cell lymphoma (MCL) are rare lymphomas which consist of less than 5% of non-Hodgkin lymphoma in Korea. Although FL with histologic grade 1 or 2 has relatively good prognosis, continual treatment is needed due to frequent relapse. FL with histologic grade 3 has poor prognosis similar to that of diffuse large B cell lymphoma. Meanwhile, the response rate to systemic chemotherapy in MCL is low, so the treatment of relapsed MCL is challenging. So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with FL or MCL

Conditions

• Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma

Interventions

Type	Name	Description
DRUG	131I-rituximab

Timeline

• Start date: 2012-06-01
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2012-09-05
• Last updated: 2012-09-05

Locations

1 site across 1 country: South Korea